Paper17538163
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M and 18 others. J Clin Oncol, 2007. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Papers, record 17538163. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538163
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
- PubMed
- Publication types
- Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Quinazolines | Major topic |
| Skin | Major topic |
| Biomarkers, Tumor | |
| Biopsy | |
| Erlotinib Hydrochloride | |
| Gene Dosage | |
| Humans | |
| Neoplasm Recurrence, Local |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N01-CO-124001 | NCI NIH HHS | United States | N01CO124001 | PubMed |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00030576 | Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Results | ClinicalTrials.gov | |
| NCT01195922 | Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17538157 | Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. | https://conductscience.org/library/papers/17538157 |
Source PubMed
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33713851 | RePhine: An Integrative Method for Identification of Drug Response-related Transcriptional Regulators. | Genomics Proteomics Bioinformatics | 2021 | https://conductscience.org/library/papers/33713851 | PubMed |
| 29467321 | Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. | JCI Insight | 2018 | https://conductscience.org/library/papers/29467321 | PubMed |
| 29232766 | Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma. | Cell Prolif | 2018 | https://conductscience.org/library/papers/29232766 | PubMed |
| 27094362 | Is there a role of synovial biopsy in drug development? | BMC Musculoskelet Disord | 2016 | https://conductscience.org/library/papers/27094362 | PubMed |
| 26120042 | In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. | Sci Rep | 2015 | https://conductscience.org/library/papers/26120042 | PubMed |
| 25702049 | Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. | Cancer Chemother Pharmacol | 2015 | https://conductscience.org/library/papers/25702049 | PubMed |
| 25482928 | Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. | Cancer Biol Ther | 2015 | https://conductscience.org/library/papers/25482928 | PubMed |
| 23342298 | Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. | Am J Nucl Med Mol Imaging | 2013 | https://conductscience.org/library/papers/23342298 | PubMed |
| 22907806 | Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. | Head Neck | 2013 | https://conductscience.org/library/papers/22907806 | PubMed |
| 22785204 | Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. | Cancer Biol Ther | 2012 | https://conductscience.org/library/papers/22785204 | PubMed |
| 22732263 | Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. | Oral Oncol | 2012 | https://conductscience.org/library/papers/22732263 | PubMed |
| 21829197 | Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21829197 | PubMed |
| 21352589 | The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. | Head Neck Oncol | 2011 | https://conductscience.org/library/papers/21352589 | PubMed |
| 21274259 | Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. | J Oncol | 2010 | https://conductscience.org/library/papers/21274259 | PubMed |
| 21188133 | Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer. | Cancer Manag Res | 2009 | https://conductscience.org/library/papers/21188133 | PubMed |
| 21048039 | Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. | Ann Oncol | 2011 | https://conductscience.org/library/papers/21048039 | PubMed |
| 20832752 | In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. | Cancer Cell | 2010 | https://conductscience.org/library/papers/20832752 | PubMed |
| 20570883 | Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. | Cancer Prev Res (Phila) | 2010 | https://conductscience.org/library/papers/20570883 | PubMed |
| 20197396 | Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. | Mol Cancer Ther | 2010 | https://conductscience.org/library/papers/20197396 | PubMed |
| 20009104 | EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. | Sci Signal | 2009 | https://conductscience.org/library/papers/20009104 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| DCTN6 | 10671 | PubTator's text mining | https://conductscience.org/library/genes/10671 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| STAT3 | 6774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL11359 | ChEMBL |
| ERLOTINIB | CHEMBL553 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL553 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538163
GET https://conductscience.org/api/papers/v1/17538163/cited_by?page=2